Clinical practice recommendations for growth hormone treatment in children with chronic kidney disease
Year: 2019
Type: review
Abstract: Achieving normal growth is one of the most challenging problems in the management of children with chronic kidney disease (CKD). Treatment with recombinant human growth hormone (GH) promotes longitudinal growth and likely enables children with CKD and short stature to reach normal adult height. Here, members of the European Society for Paediatric Nephrology (ESPN) CKD-Mineral and Bone Disorder (MBD), Dialysis and Transplantation working groups present clinical practice recommendations for the use of GH in children with CKD on dialysis and after renal transplantation. These recommendations have been developed with input from an external advisory group of paediatric endocrinologists, paediatric nephrologists and patient representatives. We recommend that children with stage 3-5 CKD or on dialysis should be candidates for GH therapy if they have persistent growth failure, defined as a height below the third percentile for age and sex and a height velocity below the twenty-fifth percentile, once other potentially treatable risk factors for growth failure have been adequately addressed and provided the child has growth potential. In children who have received a kidney transplant and fulfil the above growth criteria, we recommend initiation of GH therapy 1 year after transplantation if spontaneous catch-up growth does not occur and steroid-free immunosuppression is not a feasible option. GH should be given at dosages of 0.045-0.05 mg/kg per day by daily subcutaneous injections until the patient has reached their final height or until renal transplantation. In addition to providing treatment recommendations, a cost-effectiveness analysis is provided that might help guide decision-making.
Source: Nature Reviews Nephrology
Authors: on behalf of the European Society for Paediatric Nephrology Chronic Kidney Disease Mineral and Bone Disorders, Dialysis, and Transplantation Working Groups, Jens Drube, Mandy Wan, Marjolein Bonthuis, Elke Wühl, Justine Bacchetta, Fernando Santos, Ryszard Grenda, Alberto Edefonti, Jerome Harambat, Rukshana Shroff, Burkhard Tönshoff, Dieter Haffner
Institutions: Medizinische Hochschule Hannover, Great Ormond Street Hospital, Amsterdam UMC Location University of Amsterdam, University of Amsterdam, Heidelberg University, University Hospital Heidelberg, Hospices Civils de Lyon, Hospital Universitario Central de Asturias, Servicio de Salud del Principado de Asturias, Children's Memorial Health Institute, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Centre Hospitalier Universitaire de Bordeaux
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funders: Univerzita Karlova v Praze, Helsingin Yliopisto, National Institute for Health and Care Research, Universität Heidelberg, Radboud Universiteit, Semmelweis Egyetem, Assistance Publique - Hôpitaux de Paris, Erciyes Üniversitesi, Universität Wien, Lunds Universitet, Gazi Üniversitesi, Università degli Studi di Padova, Great Ormond Street Hospital for Children, Universiteit Gent, Università degli Studi di Firenze, Hacettepe Üniversitesi, Medizinischen Hochschule Hannover, Medizinische Universität Wien, Radboud Universitair Medisch Centrum, Hospices Civils de Lyon, Aristotle University of Thessaloniki, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Pirogov Russian National Research Medical University, Universitaire Ziekenhuizen Leuven, KU Leuven
OpenAlex ID: W2953209556
